EGFR and adenocarcinoma: The proportion of adenocarcinoma tumor samples were further categorized by mutational subtype (KRAS, EGFR, ALK, or ROS1) and the proportion of “T cell-inflamed” versus “non-inflamed” was analyzed, as well as expression level of non-synonymous somatic mutations (NSSMs)—an indicator of mutational load—and PD-L1 expression (Figure 4).